![]() |
![]() |
[ Ana Sayfa | Editörler | Danışma Kurulu | Dergi Hakkında | İçindekiler | Arşiv | Yayın Arama | Yazarlara Bilgi | E-Posta ] |
Fırat Üniversitesi Sağlık Bilimleri Tıp Dergisi |
2024, Cilt 38, Sayı 3, Sayfa(lar) 230-233 |
[ Turkish ] [ Tam Metin ] [ PDF ] |
The Role of Serum Myeloperoxidase Levels in Inflammatory Damage in HBeAg-Negative Chronic Hepatitis B Patients |
Arzu ŞENOL1, Şafak ÖZER BALİN2 |
1Fethi Sekin Şehir Hastanesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği, Elazığ, TÜRKİYE 2Fırat Üniversitesi, Tıp Fakültesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, Elazığ, TÜRKİYE |
Keywords: HBe Ag negative chronic hepatitis B, myeloperoxidase, liver inflammation |
Objective: Hepatitis B virus is seen in approximately 350 million people in the world and is responsible for the death of one million people annually. Myeloperoxidase is a heme protein that forms oxidative products during activation of neutrophils and monocytes. These products are involved in the process of tissue damage. This study aimed to measure the serum myeloperoxidase level in HBe Ag negative chronic hepatitis B patients and to evaluate the relationship between this parameter and biochemical findings.
Materials and Methods: In this study, 70 patients with HBe Ag negative chronic hepatitis B who applied to the infectious diseases outpatient clinic between December 2017 and July 2019 and 50 controls without any chronic disease were included. Serum myeloperoxidase levels were determined by ELISA method. Results: While the age range of hepatitis B patients was 41.9±1 and 31 were women and 39 were men, the age range of the control group was 39.5±9 and 22 were women and 28 were men. Serum myeloperoxidase levels were found to be approximately 2% lower in the control group than in HBe Ag negative chronic hepatitis B patients and were statistically significant (p=0.001). Conclusion: The fact that myeloperoxidase level is lower than HBe Ag negative chronic hepatitis B in the control group may indicate that this enzyme plays an important role in liver inflammation and tissue damage. We think that determining myeloperoxidase serum levels may be a useful biomarker in monitoring disease progression. |
[ Turkish ] [ Tam Metin ] [ PDF ] |
![]() |
[ Ana Sayfa | Editörler | Danışma Kurulu | Dergi Hakkında | İçindekiler | Arşiv | Yayın Arama | Yazarlara Bilgi | E-Posta ] |